Evidence map›Paper›PMID 26276679›Full record

ReviewMayo Clinic proceedings2015

Have Treatment Studies of Depression Become Even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published During the Past 20 Years.

Mark Zimmerman, Heather L Clark, Matthew D Multach, Emily Walsh, Lia K Rosenstein, Douglas Gazarian

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Mayo Clinic proceedings, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05734313 (Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults With Type 1 Diabetes), which is not on this map. Cited by 29 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05734313 narecruitingnot on this mapstarted 2023, after this paper: background citation

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults With Type 1 Diabetes

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2023 to 2027Enrolled94ConditionsDiabetes, Type 1 DiabetesArmsUnified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM)
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Trends in (not) using scales in major depression: A categorization and clinical orientation.European psychiatry : the journal of the Association of European Psychiatrists · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Mark ZimmermanDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence. Electronic address: mzimmerman@lifespan.org.
Heather L ClarkDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence.
Matthew D MultachDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence.
Emily WalshDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence.
Lia K RosensteinDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence.
Douglas GazarianDepartment of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the inclusion and exclusion criteria used in antidepressant efficacy trials (AETs) published during the past 5 years with those used in studies published during the previous 15 years. PATIENTS AND

methodsWe conducted a comprehensive literature review of placebo-controlled AETs published from January 1995 through December 2014. We included trials whether or not the medication has received regulatory approval for the treatment of depression. We compared the inclusion and exclusion criteria of studies published during the past 5 years (2010-2014) with those of studies published during the previous 15 years (1995-2009).

resultsWe identified 170 placebo-controlled AETs published during the past 20 years, 56 of which were published during the past 5 years. The more recent studies were significantly more likely to exclude patients with comorbid Axis I disorders and personality disorders, patients with the episode duration either too long or too short, and patients who had made a suicide attempt in the past. The severity threshold on depression rating scales required for inclusion was higher in the more recent studies.

conclusionThe inclusion and exclusion criteria of AETs have become more stringent over the past 5 years, thereby suggesting that AETs may be even less generalizable than they were previously (when concerns about their generalizability had already been raised).

Indexed as

Patient SelectionClinical Trials as TopicDepressive DisorderDouble-Blind MethodFemaleHumansMaleRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsTreatment OutcomeSelective Serotonin Reuptake Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.